Anemia in Inflammatory Bowel Disease or Rheumatoid Arthritis When Anti-TNF Therapy Has Not Corrected It

Patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) commonly develop mild anemia of chronic disease. Anti-TNF therapy is known to correct very mild anemia in this setting — but when it does not achieve correction of the anemia, a structured next-line approach is required.

Clinical scenario

Mild anemia of chronic disease in a patient with inflammatory bowel disease or rheumatoid arthritis, where ongoing disease management has not resolved the anemia.

Previous treatment — goal not reached

Anti-TNF therapy was the prior line in this setting. It can correct very mild anemia in patients with IBD or RA; however, when correction of the anemia is not achieved, escalation to a next-line regimen is indicated.

Next-step treatment approach (partial)

The next-line protocol involves iron therapy as one potential component of the approach — the full regimen, complete options, and selection criteria remain in the structured protocol below.

Treatment goal

Improvement of anemia with an increase in hemoglobin.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.kint.2025.06.006

Anemic patients with inflammatory bowel disease and rheumatoid arthritis have very mild anemias that are corrected by anti-TNF therapy.

Patients with more severe anemia often have other pathophysiologic components that are treatable with iron or ESA therapy, as illustrated in Figure 2.

View source ↗